<p><strong>诺和诺德公司</strong> NVO 的股票在周三早盘交易中下跌，延续了周二的剧烈抛售。投资者需要了解以下信息。</p>
<p><strong>需要知道的事项：</strong> 下行势头源于周二的公告，该丹麦制药巨头第二次下调了 2025 年的财务展望，导致其股价暴跌多达 25%。</p>
<p>修订后的预测将 2025 年的销售增长预期从 13-21% 的范围下调至 8-14%，主要归因于持续的逆风。</p>
<p>该公司指出，美国对复合 GLP-1 替代品的持续使用削弱了其畅销减肥药 Wegovy 和糖尿病治疗药物 Ozempic 的需求。</p>
<p>市场扩张速度低于预期以及竞争加剧，尤其是来自 <strong>礼来公司</strong> LLY 的 Zepbound，也对下调产生了影响。</p>
<p>此外，巴克莱分析师 Emily Field 在周三将 NVO 的评级从增持下调至持平，进一步加剧了对公司短期增长前景的担忧。这一动荡恰逢领导层变动，<strong>Maziar Mike Doustdar</strong> 将于 8 月 7 日接任首席执行官。</p>
<p>他面临的直接挑战是通过应对激烈的竞争环境和解决影响公司主要收入来源的未监管复合药物问题来恢复投资者信心。</p>
<p><strong>Benzinga Edge 排名：</strong> 根据 Benzinga Edge 的股票排名，诺和诺德呈现出混合但显著的财务特征。该股票在质量方面得分较高，评分为 73.01，表明其是一家财务健康且盈利的公司。其增长得分为中等，评分为 53.84。</p>
<p>然而，数据突显出投资者的重大担忧。动量得分极低，仅为 12.38，反映出近期的剧烈抛售，这一事实得到了短期、中期和长期价格趋势指标的负面确认。</p>
<p>此外，其价值得分非常低，仅为 7.73，表明该股票相对于其基本面被认为是昂贵的，即使在最近的价格下跌之后。</p>
<p><strong>价格走势：</strong> 根据 Benzinga Pro 的数据，NVO 股票在周三早盘交易中下跌 6.18%，报 50.61 美元。该股票的 52 周最高价为 139.74 美元，最低价为 50.57 美元。</p>
<p><strong>另请阅读：Bausch Health 在 6300 万美元收购 DURECT 时增加晚期准备的酒精性肝病药物候选者</strong></p>
<p>热门投资机会</p>
<h2>如何购买 NVO 股票</h2>
<p>现在你可能对如何参与诺和诺德的市场感到好奇——无论是购买股票，还是尝试做空该公司。</p>
<p>购买股票通常通过经纪账户进行。你可以在这里找到可能的交易平台列表。许多平台允许你购买 “部分股票”，这使你可以在不购买整股的情况下拥有股票的部分。</p>
<p>以诺和诺德为例，截至发布时其交易价格为 50.61 美元，100 美元可以购买 1.976 股股票。</p>
<p>如果你想做空一家公司，过程会更复杂。你需要访问一个期权交易平台，或者找一个允许你通过借入股票进行 “做空” 的经纪人。做空股票的过程可以在这个资源中找到。否则，如果你的经纪人允许你交易期权，你可以选择购买看跌期权，或在当前股票交易价格之上卖出看涨期权——无论哪种方式都可以让你从股价下跌中获利。</p>
<p><em>图片来源：Shutterstock</em></p>

诺和诺德公司

<p>诺和诺德公司的股票创下 52 周新低，交易价格下跌 6.18%，至 50.61 美元，此次下跌是由于公司第二次下调 2025 年的财务展望，将预计销售增长从 13-21% 下调至 8-14%。此次下调归因于来自复合 GLP-1 替代品的竞争以及市场扩展速度放缓。巴克莱分析师 Emily Field 将该股票评级从 “增持” 下调至 “持平”，对增长前景表示担忧。公司还在进行领导层变动，Maziar Mike Doustdar 将于 8 月 7 日担任首席执行官</p>

<p>Shares of <strong>Novo Nordisk A/S</strong> NVO are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday’s session. Here’s what investors need to know.</p>
<div class="lb-trans"><p><strong>诺和诺德公司</strong> NVO 的股票在周三早盘交易中下跌，延续了周二的剧烈抛售。投资者需要了解以下信息。</p>
</div><p><strong>What To Know:</strong> The downward momentum follows Tuesday’s announcement where the Danish pharmaceutical giant slashed its 2025 financial outlook for the second time this year, sending its stock plummeting by as much as 25%.</p>
<div class="lb-trans"><p><strong>需要知道的事项：</strong> 下行势头源于周二的公告，该丹麦制药巨头第二次下调了 2025 年的财务展望，导致其股价暴跌多达 25%。</p>
</div><p>The revised forecast, which cut projected 2025 sales growth from a range of 13-21% down to 8-14%, was primarily blamed on persistent headwinds.</p>
<div class="lb-trans"><p>修订后的预测将 2025 年的销售增长预期从 13-21% 的范围下调至 8-14%，主要归因于持续的逆风。</p>
</div><p>The company cited the unabated use of compounded GLP-1 alternatives in the United States, which has undercut demand for its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.</p>
<div class="lb-trans"><p>该公司指出，美国对复合 GLP-1 替代品的持续使用削弱了其畅销减肥药 Wegovy 和糖尿病治疗药物 Ozempic 的需求。</p>
</div><p>Slower-than-expected market expansion and heightened competition, particularly from <strong>Eli Lilly And Co’s</strong> LLY Zepbound, also contributed to the downgrade.</p>
<div class="lb-trans"><p>市场扩张速度低于预期以及竞争加剧，尤其是来自 <strong>礼来公司</strong> LLY 的 Zepbound，也对下调产生了影响。</p>
</div><p>Adding to the negative sentiment, Barclays analyst Emily Field downgraded NVO from Overweight to Equal-Weight on Wednesday, fueling concerns about the company’s near-term growth prospects. The turmoil coincides with a leadership shakeup, with <strong>Maziar Mike Doustdar</strong> set to take over as CEO on August 7.</p>
<div class="lb-trans"><p>此外，巴克莱分析师 Emily Field 在周三将 NVO 的评级从增持下调至持平，进一步加剧了对公司短期增长前景的担忧。这一动荡恰逢领导层变动，<strong>Maziar Mike Doustdar</strong> 将于 8 月 7 日接任首席执行官。</p>
</div><p>He faces the immediate challenge of restoring investor confidence by navigating the intense competitive landscape and tackling the unresolved issue of unregulated compounded drugs impacting the company’s key revenue streams.</p>
<div class="lb-trans"><p>他面临的直接挑战是通过应对激烈的竞争环境和解决影响公司主要收入来源的未监管复合药物问题来恢复投资者信心。</p>
</div><p><strong>Benzinga Edge Rankings:</strong> According to Benzinga Edge stock rankings, Novo Nordisk presents a mixed but telling financial profile. The stock scores strongly on Quality with a rating of 73.01, indicating it is a financially healthy and profitable company. Its Growth score is moderate at 53.84.</p>
<div class="lb-trans"><p><strong>Benzinga Edge 排名：</strong> 根据 Benzinga Edge 的股票排名，诺和诺德呈现出混合但显著的财务特征。该股票在质量方面得分较高，评分为 73.01，表明其是一家财务健康且盈利的公司。其增长得分为中等，评分为 53.84。</p>
</div><p>However, the data highlights significant concerns for investors. The Momentum score is extremely low at 12.38, reflecting the recent sharp sell-off, a fact corroborated by negative price trend indicators across short, medium, and long-term horizons.</p>
<div class="lb-trans"><p>然而，数据突显出投资者的重大担忧。动量得分极低，仅为 12.38，反映出近期的剧烈抛售，这一事实得到了短期、中期和长期价格趋势指标的负面确认。</p>
</div><p>Furthermore, its Value score is a very low 7.73, suggesting the stock is considered expensive relative to its fundamentals, even after the recent price drop.</p>
<div class="lb-trans"><p>此外，其价值得分非常低，仅为 7.73，表明该股票相对于其基本面被认为是昂贵的，即使在最近的价格下跌之后。</p>
</div><p><strong>Price Action:</strong> According to data from Benzinga Pro, NVO shares are trading lower by 6.18% to $50.61 Wednesday morning. The stock has a 52-week high of $139.74 and a 52-week low of $50.57.</p>
<div class="lb-trans"><p><strong>价格走势：</strong> 根据 Benzinga Pro 的数据，NVO 股票在周三早盘交易中下跌 6.18%，报 50.61 美元。该股票的 52 周最高价为 139.74 美元，最低价为 50.57 美元。</p>
</div><p><strong>Read Also: Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout</strong></p>
<div class="lb-trans"><p><strong>另请阅读：Bausch Health 在 6300 万美元收购 DURECT 时增加晚期准备的酒精性肝病药物候选者</strong></p>
</div><p>Trending Investment Opportunities</p>
<div class="lb-trans"><p>热门投资机会</p>
</div><h2>How To Buy NVO Stock</h2>
<div class="lb-trans"><h2>如何购买 NVO 股票</h2>
</div><p>By now you're likely curious about how to participate in the market for Novo Nordisk – be it to purchase shares, or even attempt to bet against the company.</p>
<div class="lb-trans"><p>现在你可能对如何参与诺和诺德的市场感到好奇——无论是购买股票，还是尝试做空该公司。</p>
</div><p>Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.</p>
<div class="lb-trans"><p>购买股票通常通过经纪账户进行。你可以在这里找到可能的交易平台列表。许多平台允许你购买 “部分股票”，这使你可以在不购买整股的情况下拥有股票的部分。</p>
</div><p>In the case of Novo Nordisk, which is trading at $50.61 as of publishing time, $100 would buy you 1.976 shares of stock.</p>
<div class="lb-trans"><p>以诺和诺德为例，截至发布时其交易价格为 50.61 美元，100 美元可以购买 1.976 股股票。</p>
</div><p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.</p>
<div class="lb-trans"><p>如果你想做空一家公司，过程会更复杂。你需要访问一个期权交易平台，或者找一个允许你通过借入股票进行 “做空” 的经纪人。做空股票的过程可以在这个资源中找到。否则，如果你的经纪人允许你交易期权，你可以选择购买看跌期权，或在当前股票交易价格之上卖出看涨期权——无论哪种方式都可以让你从股价下跌中获利。</p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：Shutterstock</em></p>
</div>

诺和诺德公司的股票因利润警告创下 52 周新低：投资者需要了解的事项